{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:36:15Z","timestamp":1792856175946,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd005633","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T00:00:00Z","timestamp":1254873600000}}],"reference-count":124,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005633.pub2","type":"journal-article","created":{"date-parts":[[2009,10,21]],"date-time":"2009-10-21T18:24:10Z","timestamp":1256149450000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Vitamin D compounds for people with chronic kidney disease requiring dialysis"],"prefix":"10.1002","author":[{"given":"Suetonia C","family":"Palmer","sequence":"first","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School; Renal Division; Harvard Institute of Medicine, Room 550 4 Blackfan Street Boston MA USA 02115"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O","family":"McGregor","sequence":"additional","affiliation":[{"name":"Christchurch Hospital; Department of Nephrology; Private Bag 4710 Christchurch New Zealand 8001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"School of Public Health, The University of Sydney; Centre for Kidney Research, The Children's Hospital at Westmead; Locked Bag 4001 Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grahame","family":"Elder","sequence":"additional","affiliation":[{"name":"Garvan Institute of Medical Research; Bone and Mineral Program; 384 Victoria St Darlinghurst NSW Australia 2010"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Macaskill","sequence":"additional","affiliation":[{"name":"School of Public Health; Screening and Test Evaluation Program (STEP); University of Sydney Edward Ford Building, A27 Sydney NSW Australia 2006"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Centre for Kidney Research; Locked Bag 4001 Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,10,7]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD005633.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/ajkd.1998.v32.pm9708607","article-title":"Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism","volume":"32","author":"Akiba","year":"1998","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005633.pub2-BIB0002|cit2","first-page":"S303","article-title":"Falecalcitriol (FC), but not alfacalcidol (AC), suppresses secondary hyperparathyroidism in hemodialysis (HD) patients (Pts) - a well-controlled crossover study [abstract]","volume":"3","author":"Akiba","year":"1997","journal-title":"Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD005633.pub2-BIB0003|cit3","first-page":"1810","article-title":"Suppressive effect of 22-oxacalcitriol (OCT) on secondary hyperparathyroidism (2 HPT) of hemodialysis (HD) patients. A double-blind comparison among four doses [abstract]","volume":"7","author":"Akizawa","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD005633.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1774-9987.2004.00191.x","article-title":"Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism","volume":"8","author":"Akizawa","year":"2004","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"3","key":"10.1002\/14651858.CD005633.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000190286","article-title":"'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study. [erratum appears in Nephron 1998 Aug;79(4):509]","volume":"77","author":"Bacchini","year":"1997","journal-title":"Nephron"},{"issue":"4","key":"10.1002\/14651858.CD005633.pub2-BIB0006|cit6","first-page":"185","article-title":"Controlled trial of calcitriol in hemodialysis patients","volume":"26","author":"Baker","year":"1986","journal-title":"Clinical Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD005633.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"774","DOI":"10.7326\/0003-4819-88-6-774","article-title":"1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study","volume":"88","author":"Berl","year":"1978","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD005633.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000403274","article-title":"Controlled trial of the effects of 1,25-dihydroxycholecalciferol in patients treated with regular dialysis","volume":"18","author":"Berl","year":"1980","journal-title":"Contributions to Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD005633.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/147323000303100604","article-title":"Comparative efficacy of oral and intravenous calcitriol treatment in haemodialysis patients: effects on serum biochemistry and cytokine levels","volume":"31","author":"Borazan","year":"2003","journal-title":"Journal of International Medical Research"},{"issue":"6","key":"10.1002\/14651858.CD005633.pub2-BIB0010|cit10","first-page":"523","article-title":"Treatment of uremic osteodystrophy. A clinical trial with calcitonin, 25-hydroxycholecalciferol and 1,25-dihydroxycholecalciferol","volume":"10","author":"Buccianti","year":"1981","journal-title":"Dialysis and Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD005633.pub2-BIB0011|cit11","first-page":"665","article-title":"Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism","volume":"10","author":"Caravaca","year":"1995","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD005633.pub2-BIB0012|cit12","first-page":"96","article-title":"Treatment of renal osteodystrophy (ROD) with 25-OHD3 and 1,25 (OH)2D3: Synergic effect unrelated to 24,25 (OH)2D3 synthesis","volume":"22","author":"Coen","year":"1982","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD005633.pub2-BIB0013|cit13","first-page":"301","article-title":"A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients","volume":"54","author":"Delmez","year":"2000","journal-title":"Clinical Nephrology"},{"issue":"Program and Abs","key":"10.1002\/14651858.CD005633.pub2-BIB0014|cit14","first-page":"695","article-title":"Long-term effects of early use of iv calcitriol (ivc) in the prevention of secondary hyperparathyroidism (hp) in hemodialysis patients (hd) [abstract]","volume":"4","author":"Delmez","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD005633.pub2-BIB0015|cit15","first-page":"361","article-title":"Early administration of intravenous calcitriol(IVC) prevents secondary hyperparathyroidism(HP) in hemodialysis(HD) patients [abstract]","volume":"3","author":"Delmez","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD005633.pub2-BIB0016|cit16","first-page":"142","article-title":"Oral and intravenous application of alfacalcidol in the therapy of renal hyperparathyroidism [abstract]","volume":"18","author":"Deuber","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD005633.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3109\/08860229409044901","article-title":"Treatment of secondary hyperparathyroidism with intermittent oral high doses of 1-alpha-OHD3 plus pharmacological dose of 24,25(OH)2D3","volume":"16","author":"Djukanovic","year":"1994","journal-title":"Renal Failure"},{"issue":"6","key":"10.1002\/14651858.CD005633.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1159\/000169179","article-title":"Comparison of the efficacy of two injectable forms of vitamin D3 and oral One-Alpha in treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis","volume":"17","author":"El-Reshaid","year":"1997","journal-title":"American Journal of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD005633.pub2-BIB0019|cit19","first-page":"216","article-title":"Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism","volume":"40","author":"Fischer","year":"1993","journal-title":"Clinical Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD005633.pub2-BIB0020|cit20","first-page":"39","article-title":"Prevention of radiologically obvious hyperparathyroidism in dialyses patients by i.v. 1alphaOH vitamin D3 (Etalpha) in association with Mg(OH)2 as sole phosphate binder","volume":"22","author":"Fournier","year":"1993","journal-title":"Nieren und Hochdruckkrankheiten"},{"issue":"10","key":"10.1002\/14651858.CD005633.pub2-BIB0021|cit21","first-page":"818","article-title":"Treatment of hyperparathyroidism in dialysis patients by intravenous 1a OH vitamin D3 in association with Mg(OH)2 as sole phosphate binder [abstract]","volume":"6","author":"Moriniere","year":"1991","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD005633.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000186732","article-title":"Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +\/- Mg(OH)2","volume":"60","author":"Morniere","year":"1992","journal-title":"Nephron"},{"issue":"9","key":"10.1002\/14651858.CD005633.pub2-BIB0023|cit23","first-page":"A31","article-title":"One-alpha-hydroxyvitamin D2 (1a-OH-D2): initial results from US Phase 3 trials in hemodialysis patients with secondary hyperparathyroidism [abstract]","volume":"12","author":"Chesney","year":"1997","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005633.pub2-BIB0024|cit24","first-page":"S298","article-title":"One-alpha hydroxy-vitamin D2 (1-OH-D2): an effective and safe oral agent for suppressing PTH in dialysis patients with 2o hyperparathyroidism [abstract]","volume":"3","author":"Frazao","year":"1997","journal-title":"Nephrology"},{"issue":"Supplement 3","key":"10.1002\/14651858.CD005633.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ndt\/13.suppl_3.68","article-title":"Intermittent oral 1alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients","volume":"13","author":"Frazao","year":"1998","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD005633.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/ajkd.2000.16193","article-title":"Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism","volume":"36","author":"Frazao","year":"2000","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD005633.pub2-BIB0027|cit27","first-page":"303","article-title":"Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients","volume":"16","author":"Gadallah","year":"2000","journal-title":"Advances in Peritoneal Dialysis"},{"issue":"3","key":"10.1002\/14651858.CD005633.pub2-BIB0028|cit28","first-page":"188","article-title":"Twice versus thrice weekly administration of intravenous calcitriol in dialysis patients: a randomized prospective trial. Gruppo Italiano di Studio dell'Osteodistrofia Renale","volume":"53","author":"Gallieni","year":"2000","journal-title":"Clinical Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD005633.pub2-BIB0029|cit29","first-page":"618A","article-title":"Twice versus thrice weekly administration of intraveous calcitriol in dialysis patients: a randomized prospective trial [abstract]","volume":"10","author":"Gallieni","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD005633.pub2-BIB0030|cit30","first-page":"199A","article-title":"Paricalcitol (Zemplar \u00ae) capsule reduces iPTH in CKD stage 5 patients with severe (iPTH>1000) secondary hyperparathyroidism. [abstract no: F-PO628]","volume":"14","author":"Gonzalez","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD005633.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00467-004-1792-6","article-title":"Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis","volume":"20","author":"Greenbaum","year":"2005","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD005633.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1053\/j.ajkd.2007.03.008","article-title":"Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis","volume":"49","author":"Greenbaum","year":"2007","journal-title":"American Journal of Kidney Diseases"},{"issue":"Nov","key":"10.1002\/14651858.CD005633.pub2-BIB0033|cit33","first-page":"199A","article-title":"Paricalcitol (Zemplar \u00ae) injection for the treatment of secondary hyperparathyroidism in pediatric hemodialysis patients [abstract]","volume":"14","author":"Kommala","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD005633.pub2-BIB0034|cit34","first-page":"492","article-title":"Pulse intravenous vs pulse oral alfacalcidol in hemodialysis patients with secondary hyperparathyroidism","volume":"33","author":"Haddad","year":"2004","journal-title":"Dialysis and Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD005633.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1093\/ndt\/gfh329","article-title":"Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial","volume":"19","author":"Hayashi","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD005633.pub2-BIB0036|cit36","first-page":"201A","article-title":"Comparison of the effects of calcitriol and maxacalcitol on the secondary hyperparathyroidism in the patients on chronic hemodialysis therapy: a randomized prospective multicenter trial. [abstract]","volume":"14","author":"Hayashi","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD005633.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000187887","article-title":"Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial","volume":"67","author":"Herrmann","year":"1994","journal-title":"Nephron"},{"issue":"9","key":"10.1002\/14651858.CD005633.pub2-BIB0038|cit38","first-page":"1792","article-title":"Comparison of calcium carbonate with oral (PO) and intravenous (IV) calcitriol in mild secondary hyperparathyroidism (HPT)\u00a0[abstract]","volume":"7","author":"Indridason","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD005633.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1046\/j.1523-1755.2000.00819.x","article-title":"Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients","volume":"57","author":"Indridason","year":"2000","journal-title":"Kidney International"},{"issue":"Program and Abs","key":"10.1002\/14651858.CD005633.pub2-BIB0040|cit40","first-page":"575A","article-title":"Prospective randomized trial comparing calcium carbonate (CaCO3) with oral and intravenous calcitriol in hemodialysis patients with uremic hyperparathyroidism (2\u00baHPT) [abstract]","volume":"8","author":"Indridason","year":"1997","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD005633.pub2-BIB0041|cit41","first-page":"44","article-title":"Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis","volume":"42","author":"Jones","year":"1994","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD005633.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/jren.2003.50026","article-title":"Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate","volume":"13","author":"Khajehdehi","year":"2003","journal-title":"Journal of Renal Nutrition"},{"issue":"6","key":"10.1002\/14651858.CD005633.pub2-BIB0043|cit43","first-page":"A85","article-title":"Metabolic effect of oral calcitriol pulse therapy in HD patients [abstract]","volume":"16","author":"Khajehdehi","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD005633.pub2-BIB0044|cit44","first-page":"c93","article-title":"Intravenous vitamin D therapy reduces PTH-(1-84)\/large C fragments ratio in chronic hemodialysis patients","volume":"98","author":"Kihara","year":"2004","journal-title":"Nephron"},{"issue":"6","key":"10.1002\/14651858.CD005633.pub2-BIB0045|cit45","first-page":"C75","article-title":"Comparison of intermittent and continuous (daily) oral calcitriol for treatment of renal hyperparathyroidism in children on dialysis [abstract]","volume":"9","author":"Klaus","year":"1995","journal-title":"Pediatric Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD005633.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000054729","article-title":"Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. A double-blind study among 4 doses","volume":"90","author":"Koshikawa","year":"2002","journal-title":"Nephron"},{"issue":"6","key":"10.1002\/14651858.CD005633.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1681\/ASN.V561344","article-title":"A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism","volume":"5","author":"Lee","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD005633.pub2-BIB0048|cit48","first-page":"937","article-title":"Canadian multicenter randomized control trial (rct) comparing pulse iv and pulse oral calcitriol (c) therapy in hyperparathyroid (hpth) hemodialysis (hd) patients [abstract]","volume":"6","author":"Levin","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD005633.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1681\/ASN.V73488","article-title":"Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients","volume":"7","author":"Levine","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD005633.pub2-BIB0050|cit50","first-page":"723","article-title":"Intravenous or oral calcitriol treatment in chronic hemodialysis patients with secondary hyperparathyroidism: comparative study [abstract]","volume":"4","author":"Liou","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD005633.pub2-BIB0051|cit51","first-page":"97","article-title":"Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients","volume":"20","author":"Liou","year":"1994","journal-title":"Mineral & Electrolyte Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD005633.pub2-BIB0052|cit52","first-page":"966","article-title":"Comparative effect of subcutaneous or oral pulse calcitriol (scc, opc) treatment on secondary hyperparathyroidism in continuous ambulatory peritoneal dialysis patients (capd+shp): a prospective, crossover study [abstract]","volume":"6","author":"Liou","journal-title":"1995"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005633.pub2-BIB0053|cit53","first-page":"S73","article-title":"19-nor-1a, 25 - dihydroxyvitamin D2 (19-nor): an effective vitamin D analog suppresses PTH secretion in hemodialysis (HD) patients [abstract]","volume":"3","author":"Llach","year":"1997","journal-title":"Nephrology"},{"issue":"2 (Suppl 2)","key":"10.1002\/14651858.CD005633.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1053\/ajkd.1998.v32.pm9808143","article-title":"Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2","volume":"32","author":"Llach","year":"1998","journal-title":"American Journal of Kidney Diseases"},{"issue":"8","key":"10.1002\/14651858.CD005633.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5 (Suppl 5)","key":"10.1002\/14651858.CD005633.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1053\/ajkd.2001.28112","article-title":"Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study","volume":"38","author":"Martin","year":"2001","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD005633.pub2-BIB0057|cit57","first-page":"1206","article-title":"Once a week pulse of intravenous calcitriol in haemodialysis patients (HD) [abstract]","volume":"11","author":"Martinez","year":"1996","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD005633.pub2-BIB0059|cit58","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/cpt1978235515","article-title":"Calcitriol in dialysis patients","volume":"23","author":"Maxwell","year":"1978","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD005633.pub2-BIB0058|cit59","first-page":"166","article-title":"Randomized double blind study of 1, 25(OH)2D3 in dialysis patients","volume":"7","author":"Maxwell","year":"1977","journal-title":"Proceedings of the Clinical Dialysis & Transplant Forum"},{"issue":"6280","key":"10.1002\/14651858.CD005633.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1136\/bmj.282.6280.1919","article-title":"Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis","volume":"282","author":"Memmos","year":"1981","journal-title":"British Medical Journal Clinical Research Ed"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD005633.pub2-BIB0061|cit61","first-page":"iv135","article-title":"Initial dosing of paricalcitol based on parathormone levels in haemodialysis patients with mild and moderate secondary hyperparathyroidism: is iPTH\/80 the most appropriate? [abstract]","volume":"21","author":"Mitsopoulos","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD005633.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1053\/j.ajkd.2006.04.060","article-title":"Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism","volume":"48","author":"Mitsopoulos","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD005633.pub2-BIB0063|cit63","first-page":"12","article-title":"Prospective comparison of the effects of maxacalcitol and calcitriol in chronic hemodialysis patients with secondary hyperparathyroidism: a multicenter, randomized crossover study","volume":"67","author":"Mochizuki","year":"2007","journal-title":"Clinical Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD005633.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/ndt\/13.5.1234","article-title":"Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial","volume":"13","author":"Moe","year":"1998","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD005633.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1053\/ajkd.2001.27697","article-title":"A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol","volume":"38","author":"Moe","year":"2001","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD005633.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000183396","article-title":"Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis","volume":"39","author":"Moriniere","year":"1985","journal-title":"Nephron"},{"issue":"5","key":"10.1002\/14651858.CD005633.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000168873","article-title":"The effect of peroral calcitriol in small doses on mild secondary hyperparathyroidism in patients on hemodialysis","volume":"15","author":"Pecovnik-Balon","year":"1995","journal-title":"American Journal of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD005633.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/8756-3282(92)90453-4","article-title":"Assessment of combined 24,25(OH)2D3 and 1 alpha (OH)D3 therapy for bone disease in dialysis patients","volume":"13","author":"Popovtzer","year":"1992","journal-title":"Bone"},{"issue":"8","key":"10.1002\/14651858.CD005633.pub2-BIB0069|cit69","first-page":"710","article-title":"Treatment with 1 Hydroxy Vit D3 (1D) and 24-25 dihydroxy vit D3 (24D) in haemodialysed patients [abstract]","volume":"5","author":"Popovzer","year":"1990","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD005633.pub2-BIB0070|cit70","first-page":"484A","article-title":"Rapid control of secondary hyperparathyroidism with paricalcitol (Zemplar (R)) capsule in patients on peritoneal dialysis [abstract]","volume":"14","author":"Qiu","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD005633.pub2-BIB0071|cit71","first-page":"718","article-title":"Prospective double-blind placebo controlled trial of pulse oral (PO) versus intravenous (IV) calcitriol in the treatment of hyperprarthyroidism in end stage renal disease (ESRD) [abstract]","volume":"4","author":"Quarles","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD005633.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/ki.1994.223","article-title":"Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD","volume":"45","author":"Quarles","year":"1994","journal-title":"Kidney International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005633.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"S441","DOI":"10.1177\/089686089901902S72","article-title":"Consequences of intermittent calcitriol therapy in pediatric patients with secondary hyperparathyroidism","volume":"19","author":"Salusky","year":"1999","journal-title":"Peritoneal Dialysis International"},{"issue":"7","key":"10.1002\/14651858.CD005633.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s004670000352","article-title":"Implications of intermittent calcitriol therapy on growth and secondary hyperparathyroidism","volume":"14","author":"Salusky","year":"2000","journal-title":"Pediatric Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD005633.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1046\/j.1523-1755.1998.00045.x","article-title":"Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration","volume":"54","author":"Salusky","year":"1998","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD005633.pub2-BIB0076|cit76","first-page":"237","article-title":"Efficacy of a single weekly bolus of intravenous calcitriol in severe secondary hyperparathyroidism","volume":"19","author":"Sanchez Perales","year":"1999","journal-title":"Nefrologia"},{"issue":"5 Suppl 5","key":"10.1002\/14651858.CD005633.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1053\/ajkd.2001.28110","article-title":"Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol","volume":"38","author":"Sprague","year":"2001","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD005633.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD005633.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"415","DOI":"10.5414\/CNP65415","article-title":"A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease","volume":"65","author":"Tarrass","year":"2006","journal-title":"Clinical Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD005633.pub2-BIB0080|cit80","first-page":"202A","article-title":"Chronotherapy of high-dose vitamin D (VD) in hemodialysis patients with secondary hyperparathyroidism [abstract]","volume":"14","author":"Tsuruoka","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD005633.pub2-BIB0081|cit81","unstructured":"Akbulut M Turk S Vatansev H Gokbel H Gonen S Gurbilek M Comparison of the effects of oral and iv pulse calcitriol treatment on serum cytokine levels in hemodialysis patients [abstract] 36th Congress. European Renal Association. European Dialysis and Transplantation Association; 1999 Sept 5-8; Madrid (Spain) 1999 291"},{"issue":"2","key":"10.1002\/14651858.CD005633.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000049041","article-title":"Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: The effect on serum IL-1 and IL-6 levels and bone mineral density","volume":"90","author":"Turk","year":"2002","journal-title":"Nephron"},{"issue":"10","key":"10.1002\/14651858.CD005633.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/ndt\/5.10.874","article-title":"Low calcium dialysate and high-dose oral calcitriol in the treatment of secondary hyperparathyroidism in haemodialysis patients","volume":"5","author":"Merwe","year":"1990","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD005633.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000186767","article-title":"Effect of 24,25-dihydroxycholecalciferol on intestinal absorption of calcium and phosphate and on parathyroid hormone secretion in chronic renal failure","volume":"60","author":"Varghese","year":"1992","journal-title":"Nephron"},{"issue":"1","key":"10.1002\/14651858.CD005633.pub2-BIB0085|cit85","first-page":"C38","article-title":"The prevention of renal osteodystrophy (ROD) in children under going CAPD: a prospective randomised trial using 1 hydroxycholecalciferol [abstract]","volume":"1","author":"Watson","year":"1987","journal-title":"Pediatric Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD005633.pub2-BIB0086|cit86","first-page":"220","article-title":"Renal osteodystrophy in children on CAPD: a prospective trial of 1-alpha-hydroxycholecalciferol therapy","volume":"9","author":"Watson","journal-title":"Child Nephrology and Urology"},{"issue":"6","key":"10.1002\/14651858.CD005633.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1159\/000089707","article-title":"Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol","volume":"25","author":"Zisman","year":"2005","journal-title":"American Journal of Nephrology"},{"key":"10.1002\/14651858.CD005633.pub2-BIB0088|cit88","unstructured":"NCT00257920 A study of Zemplar\u00ae injection and Hectorol\u00ae injection on intestinal absorption of calcium in chronic kidney disease http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00257920"},{"key":"10.1002\/14651858.CD005633.pub2-BIB0089|cit89","unstructured":"NCT00397475 Evaluation of colecalciferol substitution in dialysis patients http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00397475"},{"issue":"1","key":"10.1002\/14651858.CD005633.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","article-title":"Increased risk of hip fracture among patients with end-stage renal disease","volume":"58","author":"Alem","year":"2000","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD005633.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study","volume":"31","author":"Block","year":"1998","journal-title":"American Journal of Kidney Diseases"},{"issue":"8","key":"10.1002\/14651858.CD005633.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD005633.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000057611","article-title":"Renal osteodystrophy in predialysis and haemodialysis patients: Comparison of histological patterns and diagnostic predictivity of intact PTH","volume":"91","author":"Coen","year":"2002","journal-title":"Nephron"},{"issue":"1","key":"10.1002\/14651858.CD005633.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5414\/CNP59059","article-title":"Cardiac and pulmonary calcification in a haemodialysis patient: partial regression 4 years after parathyroidectomy","volume":"59","author":"Leo","year":"2003","journal-title":"Clinical Nephrology"},{"issue":"6964","key":"10.1002\/14651858.CD005633.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"British Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD005633.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/ndt\/gfh123","article-title":"Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings","volume":"19","author":"Dobrez","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"7109","key":"10.1002\/14651858.CD005633.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"British Medical Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005633.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1111\/j.1440-1797.2006.00508.x","article-title":"The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone","volume":"11","author":"Elder","year":"2006","journal-title":"Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD005633.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD005633.pub2-BIB0100|cit100","doi-asserted-by":"crossref","unstructured":"Geary DF Hodson EM Craig JC Interventions for bone disease in children with chronic kidney disease http:\/\/www.cochrane.org\/reviews\/en\/topics\/89.html (accessed August 2009)","DOI":"10.1002\/14651858.CD008327"},{"issue":"1","key":"10.1002\/14651858.CD005633.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000190244","article-title":"Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis","volume":"77","author":"Goldsmith","year":"1997","journal-title":"Nephron"},{"issue":"7414","key":"10.1002\/14651858.CD005633.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD005633.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/ndt\/gfg296","article-title":"In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3","volume":"18","author":"Hirata","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD005633.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney International"},{"issue":"9","key":"10.1002\/14651858.CD005633.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/archneur.1980.00500580051007","article-title":"Proximal muscle weakness in uremia. Case reports and review of the literature","volume":"37","author":"Lazaro","year":"1980","journal-title":"Archives of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD005633.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/j.jrn.2006.07.006","article-title":"Impact of kidney bone disease and its management on survival of patients on dialysis","volume":"17","author":"Lee","year":"2007","journal-title":"Journal of Renal Nutrition"},{"key":"10.1002\/14651858.CD005633.pub2-BIB0107|cit107","unstructured":"Lefebvre C McDonald S Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE Fourth International Cochrane Colloquium; 1996 Oct 20-24; Adelaide (Australia) 1996"},{"key":"10.1002\/14651858.CD005633.pub2-BIB0108|cit108","unstructured":"United States Cochrane Center Master list of journals being searched http:\/\/apps1.jhsph.edu\/cochrane\/masterlist.asp (accessed May 2009)"},{"issue":"2","key":"10.1002\/14651858.CD005633.pub2-BIB0109|cit109","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006023","article-title":"Phosphate binders for preventing and treating bone disease in chronic kidney disease patients","author":"Navaneethan","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4 Suppl 3","key":"10.1002\/14651858.CD005633.pub2-BIB0110|cit110","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD005633.pub2-BIB0111|cit111","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005015.pub3","article-title":"Interventions for preventing bone disease in kidney transplant recipients","author":"Palmer","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD005633.pub2-BIB0112|cit112","article-title":"Vitamin D compounds for people with chronic kidney disease not requiring dialysis","author":"Palmer","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD005633.pub2-BIB0113|cit113","first-page":"57","article-title":"Fractures and vertebral bone mineral density in patients with renal osteodystrophy","volume":"30","author":"Piraino","year":"1988","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD005633.pub2-BIB0114|cit114","unstructured":"Willis NS Mitchell R Higgins GY Webster AC Craig JC Cochrane Renal Group About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2009, Issue 3. Art. No.: RENAL (accessed July 2009)"},{"issue":"1","key":"10.1002\/14651858.CD005633.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ndt\/gfg513","article-title":"Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population","volume":"19","author":"Shoji","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD005633.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1046\/j.1523-1755.2003.00029.x","article-title":"Efficacy of 19-nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia","volume":"63","author":"Slatopolsky","year":"2003","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD005633.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.ajkd.2006.01.015","article-title":"Meta-analysis of biochemical and patient-level effects of calcimimetic therapy","volume":"47","author":"Strippoli","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD005633.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD005633.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","article-title":"Activated injectable vitamin D and hemodialysis survival: a historical cohort study","volume":"16","author":"Teng","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD005633.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.ki.5001868","article-title":"Mortality risk among hemodialysis patients receiving different vitamin D analogs","volume":"70","author":"Tentori","year":"2006","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD005633.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/01.ASN.0000123691.46138.E2","article-title":"Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies","volume":"15","author":"Weiner","year":"2004","journal-title":"Journal of the Amercian Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD005633.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1523-1755.2005.00185.x","article-title":"Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study","volume":"67","author":"Young","year":"2005","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD005633.pub2-BIB0123|cit123","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005633","article-title":"Vitamin D analogues for the treatment and prevention of bone disease in chronic kidney disease","author":"Palmer","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD005633.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-147-12-200712180-00004","article-title":"Meta-analysis: vitamin D compounds in chronic kidney disease","volume":"147","author":"Palmer","year":"2007","journal-title":"Annals of Internal Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD005633.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T18:30:14Z","timestamp":1634063414000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD005633.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2009,10,7]]},"references-count":124,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005633.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,7]]}}}